TheNFAPost Podcast
4

As India faces a second wave of COVID-19, PerkinElmer, will donate 1 million PerkinElmer COVID-19 Antigen Tests to the Government of India (GoI) to help accelerate testing capabilities across the country.

With the support of the US-India Strategic Partnership Forum (USISPF), PerkinElmer COVID-19 Antigen Test kits will be distributed to government hospitals and testing centers across 10 states of India, a release said.

“The second wave of COVID-19 in India has mobilized our teams around the world to help in whichever ways we can,” said Deepak Tripathi, CEO of Tulip Diagnostics, a PerkinElmer company.

“We’re working around the clock to assist employees and customers across India through this incredibly challenging time, with the hope that by providing vital goods and services needed to create a seamless testing network, we can help stop the spread of this terrible disease,” he added.

The PerkinElmer COVID-19 Antigen Test is a lateral flow immunoassay ideally suited for point-of-care (POC) and non-clinical settings. The CE marked assay may be used with nasal or nasopharyngeal swab specimens to screen or to aid in the diagnosis of both asymptomatic and symptomatic individuals, and it is capable of delivering a positive or negative result in as little as 15 minutes.

“Since the Company’s founding, PerkinElmer has been dedicated to making the world a better place to live, and today it is even more important that we continue this tradition,” said Shripad Joshi, president of PerkinElmer India & South-Asia.

“Since the earliest days of the pandemic, we have focused on keeping employees safe and providing critical diagnostic supplies to over 1,000 organisations that needed them. The current crisis in India motivates us to extend beyond our own horizons and support our government to fasten up testing,” Joshi added.

 

Previous articleToonz Media Group Launches Elearning Platform Ri8brain Dedicated to Creative Arts
Next articleTA Associates Announces Strategic Growth Investment In InCorp Global

LEAVE A REPLY

Please enter your comment!
Please enter your name here